Skip to content

AngioSeal Versus Radial Approach in Acute Coronary Syndrome

Randomized Trial Between the Transfemoral Approach With AngioSeal and the Transradial Approach to Prevent Vascular Access Complications in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Submitted To Early Invasive Strategy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01653587
Acronym
ARISE
Enrollment
240
Registered
2012-07-31
Start date
2012-07-31
Completion date
2016-03-31
Last updated
2018-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

Transradial Approach, Transfemoral Approach, Vascular Closure Device

Brief summary

Among non-ST-segment elevation acute coronary syndrome patients submitted to early invasive strategy and randomized for the transfemoral or transradial approach, the AngioSeal vascular closure device would decrease the prevalence of vascular complications at puncture site, reaching the non-inferiority criterion when compared to the radial access.

Detailed description

Antithrombotic therapy and percutaneous or surgical myocardial revascularization procedures are the basis of the treatment of patients admitted with non-ST-segment elevation acute coronary syndrome. However, the desired reduction of the recurrence of ischemic events has as complication an increased incidence of bleeding. Since arterial puncture followed by the insertion of an introducer has become the standard method to perform invasive cardiovascular procedures, complications related to vascular access have become an important bleeding site. Among the strategies to decrease vascular complications, the transradial approach is a well stablished alternative to the transfemoral approach. For its part, vascular closure devices were introduced to decrease vascular complications, homeostasis time and ambulation time of patients submitted to invasive procedures by the transfemoral access. Rapidly incorporated to the clinical practice, such devices to date have shown conflicting results with regard to their safety and efficacy. The inconsistency of data proving its safety limits its routine adoption as strategy to prevent vascular complications, requiring evidences through adequately designed randomized studies for this end.

Interventions

DEVICEPercutaneous coronary intervention

Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.

Sponsors

Irmandade Santa Casa Misericórdia Marília
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Non-ST-segment elevation ACS patients \[ischemic symptoms suspicious of non-ST-segment elevation ACS (unstable angina or non-ST-segment elevation AMI) defined as clinical presentation compatible with a new manifestation of worsening of chest pain characteristic of ischemia, at rest or at minimum effort, lasting more than 10 minutes, and at least one of the following items: (a) ECG changes compatible with new ischemia (ST segment depression of at least 1 mm, or transient ST segment elevation, or ST segment elevation ≤ 1 mm, or T wave inversion \> 2 mm in at least 2 contiguous shunts); (b) cardiac enzymes (CK-MB or troponin T or I) above the upper normality range limit; (c) patients \> 60 years of age without ECG or myocardial necrosis markers changes, however with previous documentation of coronary atherosclerotic disease (CAD), confirmed by previous hospitalization due to AMI, previous percutaneous or surgical myocardial revascularization procedure, significant CAD confirmed by coronary angiography, or positive functional test for myocardial ischemia\]; * Intention to submit patient to early invasive strategy consisting of coronary angiography immediately followed by PCI, when applicable, in the first 72 hours after admission; * Signed informed consent; * Patient eligible for transradial and transfemoral coronary angiography and PCI, being pre-requisites: (a) palpable radial artery with normal Allen test or/and oximetry tests, (b) familiarity of the operator with the radial and femoral techniques using AngioSeal, (c) agreement of the operator to use the access route determined by the randomization process.

Exclusion criteria

* Less than 18 years of age; * Pregnancy; * Chronic use of vitamin K antagonists or direct thrombin inhibitors, or oral Xa-factor antagonists; * Hypersensitivity to antiplatelet and/or anticoagulant drugs; * Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance \< 30 mL/min, platelets count \< 100.000 mm3); * Uncontrolled systemic hypertension; * Cardiogenic shock; * Previous myocardial revascularization surgery with ≥ 1 internal mammary or radial artery graft; * Documented chronic peripheral arterial disease preventing the use of the femoral technique; * Severe concomitant disease with life expectancy below 12 months; * Participation in drug or devices investigative clinical trials in the last 30 days; * Indication of elective percutaneous coronary intervention to be performed in a moment different from immediately after coronary angiography; * Medical, geographic or social conditions impairing the participation in the study or inability to understand and sign the informed consent term.

Design outcomes

Primary

MeasureTime frameDescription
First Occurrence of Access Site Related Ischemic or Bleeding Complication30 daysVascular and systemic complications at arterial puncture site include major bleeding, retroperitoneal hemorrhage, compartment syndrome, hematoma ≥ 5 cm, pseudoaneurysm, arteriovenous fistula, infection, limb ischemia, asymptomatic arterial occlusion, adjacent nerve injury or need for vascular surgery repair.

Secondary

MeasureTime frameDescription
Adverse Ischemic or Bleeding Events30 daysIndividual components of the primary objective, hematoma \< 5 cm, cardiovascular death, myocardial infarction, stroke, major bleeding unrelated to puncture site or to coronary artery bypass grafting, device success and crossover rate between techniques

Other

MeasureTime frame
Cardiovascular Death, Myocardial Infarction or Stroke12 months

Countries

Brazil

Participant flow

Participants by arm

ArmCount
Transradial Approach
Transradial approach percutaneous coronary intervention using the TR Band device to obtain hemostasis Percutaneous coronary intervention: Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
120
Transfemoral Approach
Transfemoral approach percutaneous coronary intervention using the AngioSeal vascular closure device STS Plus Platform to obtain hemostasis Percutaneous coronary intervention: Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
120
Total240

Baseline characteristics

CharacteristicTransradial ApproachTransfemoral ApproachTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
55 Participants53 Participants108 Participants
Age, Categorical
Between 18 and 65 years
65 Participants67 Participants132 Participants
Age, Continuous62.5 years
STANDARD_DEVIATION 11.2
63.6 years
STANDARD_DEVIATION 10.2
63.0 years
STANDARD_DEVIATION 10.7
Ethnicity (NIH/OMB)
Hispanic or Latino
120 Participants120 Participants240 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
120 Participants120 Participants240 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
Brazil
120 participants120 participants240 participants
Sex: Female, Male
Female
40 Participants24 Participants64 Participants
Sex: Female, Male
Male
80 Participants96 Participants176 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
2 / 1202 / 120
other
Total, other adverse events
2 / 1202 / 120
serious
Total, serious adverse events
3 / 1209 / 120

Outcome results

Primary

First Occurrence of Access Site Related Ischemic or Bleeding Complication

Vascular and systemic complications at arterial puncture site include major bleeding, retroperitoneal hemorrhage, compartment syndrome, hematoma ≥ 5 cm, pseudoaneurysm, arteriovenous fistula, infection, limb ischemia, asymptomatic arterial occlusion, adjacent nerve injury or need for vascular surgery repair.

Time frame: 30 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Transradial ApproachFirst Occurrence of Access Site Related Ischemic or Bleeding Complication16 Participants
Transfemoral ApproachFirst Occurrence of Access Site Related Ischemic or Bleeding Complication15 Participants
Secondary

Adverse Ischemic or Bleeding Events

Individual components of the primary objective, hematoma \< 5 cm, cardiovascular death, myocardial infarction, stroke, major bleeding unrelated to puncture site or to coronary artery bypass grafting, device success and crossover rate between techniques

Time frame: 30 days

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Transradial ApproachAdverse Ischemic or Bleeding Events11 Participants
Transfemoral ApproachAdverse Ischemic or Bleeding Events3 Participants
Other Pre-specified

Cardiovascular Death, Myocardial Infarction or Stroke

Time frame: 12 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Transradial ApproachCardiovascular Death, Myocardial Infarction or Stroke2 Participants
Transfemoral ApproachCardiovascular Death, Myocardial Infarction or Stroke3 Participants

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026